Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katia Youssov

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Plos One|September 15, 2016
Insulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington's DiseaseLinda Salem, Nadine Saleh, Gaelle Désaméricq, et al.
Plos One|May 27, 2015
Longitudinal study of informed consent in innovative therapy research: experience and provisional recommendations from a multicenter trial of intracerebral graftingLaurent Cleret de Langavant, Sophie Sudraud, Christophe Verny, et al.
JAMA Neurology|July 12, 2016
Expanding the Spectrum of Genes Involved in Huntington Disease Using a Combined Clinical and Genetic ApproachLouise-Laure Mariani, Christelle Tesson, Perrine Charles, et al.
Brain Communications|January 2, 2025
The joint memory effect: challenging the selfish stigma in Huntington's disease?Romain Dalléry, Nicolas Fraisse, Laurent Cléret de Langavant, et al.
Plos One|August 23, 2021
Cognitive decline in Huntington's disease in the Digitalized Arithmetic Task (DAT)Marine Lunven, Jennifer Hamet Bagnou, Katia Youssov, et al.
Brain Communications|March 20, 2023
A new approach to digitized cognitive monitoring: validity of the SelfCog in Huntington's diseaseMarine Lunven, Karen Hernandez Dominguez, Katia Youssov, et al.
Frontiers in Neurology|July 24, 2019
International Guidelines for the Treatment of Huntington's DiseaseAnne-Catherine Bachoud-Lévi, Joaquim Ferreira, Renaud Massart, et al.
Plos One|January 24, 2014
Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohortGaëlle Désaméricq, Guillaume Dolbeau, Christophe Verny, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 25, 2017
A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's diseaseChristophe Verny, Anne-Catherine Bachoud-Lévi, Alexandra Durr, et al.
Plos One|September 23, 2016
COMT Val158Met Polymorphism Modulates Huntington's Disease ProgressionRuth de Diego-Balaguer, Catherine Schramm, Isabelle Rebeix, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Plos One|September 15, 2016
Insulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington's DiseaseLinda Salem, Nadine Saleh, Gaelle Désaméricq, et al.
Plos One|May 27, 2015
Longitudinal study of informed consent in innovative therapy research: experience and provisional recommendations from a multicenter trial of intracerebral graftingLaurent Cleret de Langavant, Sophie Sudraud, Christophe Verny, et al.
JAMA Neurology|July 12, 2016
Expanding the Spectrum of Genes Involved in Huntington Disease Using a Combined Clinical and Genetic ApproachLouise-Laure Mariani, Christelle Tesson, Perrine Charles, et al.
Brain Communications|January 2, 2025
The joint memory effect: challenging the selfish stigma in Huntington's disease?Romain Dalléry, Nicolas Fraisse, Laurent Cléret de Langavant, et al.
Plos One|August 23, 2021
Cognitive decline in Huntington's disease in the Digitalized Arithmetic Task (DAT)Marine Lunven, Jennifer Hamet Bagnou, Katia Youssov, et al.
Brain Communications|March 20, 2023
A new approach to digitized cognitive monitoring: validity of the SelfCog in Huntington's diseaseMarine Lunven, Karen Hernandez Dominguez, Katia Youssov, et al.
Frontiers in Neurology|July 24, 2019
International Guidelines for the Treatment of Huntington's DiseaseAnne-Catherine Bachoud-Lévi, Joaquim Ferreira, Renaud Massart, et al.
Plos One|January 24, 2014
Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohortGaëlle Désaméricq, Guillaume Dolbeau, Christophe Verny, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 25, 2017
A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's diseaseChristophe Verny, Anne-Catherine Bachoud-Lévi, Alexandra Durr, et al.
Plos One|September 23, 2016
COMT Val158Met Polymorphism Modulates Huntington's Disease ProgressionRuth de Diego-Balaguer, Catherine Schramm, Isabelle Rebeix, et al.
Pageof 4